Celgene Corporation Drug Revlimid Increases Risk of Certain New Cancers

Published: May 09, 2012

The Food and Drug Administration said certain patients treated with Celgene Corp.'s (CELG) cancer drug Revlimid have an increased risk of developing some new types of cancers. Revlimid is approved to treat patients with multiple myeloma, a bone-marrow cancer in combination with another drug. The product is also approved to treat another bone-marrow condition called myelodysplastic syndromes. In a drug-safety communication posted to the FDA's website Monday, the agency said data from clinical trials of Revlimid showed newly diagnosed patients treated with Revlimid had an increased risk of developing second types of cancer compared to similar patients who received a placebo, or fake drug.

Back to news